Enuzovimab Biosimilar – Anti-Spike RBD mAb – Research Grade from ProteoGenix; catalogue PX-TA1802; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Enuzovimab Biosimilar, also known as Anti-Spike RBD mAb, is a research grade monoclonal antibody that has been developed as a potential therapeutic agent for the treatment of various diseases. This article will provide a detailed scientific description of the structure, activity, and potential applications of Enuzovimab Biosimilar.
Enuzovimab Biosimilar is a monoclonal antibody that specifically targets the receptor binding domain (RBD) of the spike protein of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The antibody is a recombinant protein, produced by cloning the gene for the antibody in a host cell, typically Chinese hamster ovary (CHO) cells.
The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of four constant regions (Fc) and one variable region (VH), while the light chains consist of two constant regions (CL) and one variable region (VL). The variable regions are responsible for binding to the RBD of the spike protein, while the constant regions determine the antibody’s effector functions.
Enuzovimab Biosimilar has been designed to specifically target the RBD of the spike protein of SARS-CoV-2. The spike protein is responsible for the virus’s entry into host cells, making it a crucial therapeutic target for COVID-19. By binding to the RBD, Enuzovimab Biosimilar prevents the virus from attaching to and infecting host cells, thereby neutralizing its activity.
In addition to its neutralizing activity, Enuzovimab Biosimilar also has effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These functions allow the antibody to recruit and activate immune cells to eliminate virus-infected cells, enhancing its efficacy as a therapeutic agent.
Enuzovimab Biosimilar has the potential to be used in the treatment of COVID-19, as well as other diseases caused by SARS-CoV-2, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The antibody can also be used as a prophylactic treatment to prevent infection in individuals at high risk of exposure to the virus, such as healthcare workers.
In addition to its potential use in the treatment and prevention of COVID-19, Enuzovimab Biosimilar has the potential to be used in the development of diagnostic tests for the virus. The antibody can be used in various immunoassays to detect the presence of the spike protein or antibodies against it, aiding in the diagnosis of COVID-19.
In conclusion, Enuzovimab Biosimilar is a research grade monoclonal antibody that specifically targets the RBD of the spike protein of SARS-CoV-2. Its structure, activity, and potential applications make it a promising therapeutic agent for the treatment of COVID-19 and other diseases caused by the virus. Further research and clinical trials will be necessary to fully evaluate the efficacy and safety of Enuzovimab Biosimilar, but it holds great potential in the fight against the COVID-19 pandemic.
ProteoGenix catalogue number PX-TA1802. For research use only.
Target: Enuzovimab Biosimilar – Anti-Spike RBD mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Enuzovimab Biosimilar – Anti-Spike RBD mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
